{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:50:21Z","timestamp":1792057821913,"version":"4.4.0"},"reference-count":18,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Selective serotonin receptor (5\u2010HT3) antagonists are first\u2010line antiemetics for chemotherapy\u2010induced, radiotherapy\u2010induced, and post\u2010operative nausea and vomiting; other causes of nausea in advanced cancer warrant alternative agents. We aimed to determine patterns of inpatient 5\u2010HT3 antagonist prescribing and its guideline concordance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed electronic medical records of all patients admitted under Medical Oncology at a single metropolitan hospital over 6 months who were prescribed a 5\u2010HT3 antagonist. Data on demographics, cancer, and the prescription (agent, indication, prescriber, duration, administration) were extracted and reviewed for guideline concordance. Analyses were descriptive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 210 patients admitted between January and June 2025, 81 (38.6%) were prescribed a 5\u2010HT3 antagonist. Mean age was 64.2 years (range 24\u201387); 41 (50.6%) were female, and 62 (76.5%) had metastatic cancer. Of 137 prescriptions written, 134 (97.8%) were for ondansetron. Nausea was documented in 104 (75.9%), but a specific cause in only 55\/104 (52.9%). The most common prescribers were Emergency (62, 45.3%) and After\u2010Hours (32, 23.4%) doctors. Prescriptions were brief (median 1 day); 82 (59.9%) were administered at least once, and 62\/82 (75.6%) were single\u2010dose. Overall, 93 (67.9%) were non\u2010concordant. Concordance was 10\/14 (71.4%) in Medical Oncology, 20\/21 (95.2%) in anesthetics and intensive care, 4\/4 (100%) in Radiation Oncology, and 4\/4 (100%) in Palliative Care, but 2\/62 (3.2%) in Emergency and 4\/32 (12.5%) in After\u2010Hours prescribers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>5\u2010HT3 antagonists were frequently prescribed outside guideline recommendations, particularly by clinicians less familiar with cancer. Targeted education, electronic order\u2010set redesign, and structured documentation of the suspected mechanism of nausea may improve guideline\u2010concordant antiemetic prescribing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.70208","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:38:00Z","timestamp":1792057080000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selective Serotonin Receptor (5\u2010HT3) Antagonist Prescribing in Cancer Inpatients: A Retrospective Clinical Audit"],"prefix":"10.1111","author":[{"given":"Henshaw","family":"Corey","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Concord Repatriation General Hospital Sydney Local Health District  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gray","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Concord Repatriation General Hospital Sydney Local Health District  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Tam","family":"Bui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Concord Repatriation General Hospital Sydney Local Health District  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Linton","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Concord Repatriation General Hospital Sydney Local Health District  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jpainsymman.2005.06.007","article-title":"A Comparison of Symptom Prevalence in Far Advanced Cancer, AIDS, Heart Disease, Chronic Obstructive Pulmonary Disease and Renal Disease","volume":"31","author":"Solano J. P.","year":"2006","journal-title":"Journal of Pain and Symptom Management"},{"key":"e_1_2_13_3_1","unstructured":"Therapeutic Guidelines Limited. Nausea and vomiting in palliative care.Palliative Care Version 5. Therapeutic Guidelines Ltd(2024) https:\/\/www.tg.org.au"},{"key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11864-020-0704-8","article-title":"Nausea and Vomiting in Advanced Cancer","volume":"21","author":"Navari R. M.","year":"2020","journal-title":"Current Treatment Options in Oncology"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7861\/clinmedicine.19-4-299","article-title":"Nausea and Vomiting in Palliative Care","volume":"19","author":"Leach C.","year":"2019","journal-title":"Clinical Medicine"},{"key":"e_1_2_13_6_1","first-page":"263","article-title":"Mechanism of the Anti\u2010Emetic Activity of 5\u2010HT3 Antagonists","volume":"49","author":"Tyers M. B.","year":"1992","journal-title":"Oncology"},{"key":"e_1_2_13_7_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 2(2025). NCCN Plymouth Meeting.https:\/\/www.nccn.org."},{"key":"e_1_2_13_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO Guideline Update for the Prevention of Chemotherapy\u2010 and Radiotherapy\u2010Induced Nausea and Vomiting","volume":"9","author":"Herrstedt J.","year":"2024","journal-title":"ESMO Open"},{"key":"e_1_2_13_9_1","volume-title":"Antiemetic Guidelines: Cancer\u2010Related Nausea and Vomiting","author":"eviQ","year":"2025"},{"key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1007\/s00520-021-06437-w","article-title":"MASCC Antiemetics in Advanced Cancer Updated Guideline","volume":"29","author":"Davis M. P.","year":"2021","journal-title":"Supportive Care in Cancer"},{"key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO Guideline Update","volume":"38","author":"Hesketh P. J.","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/CIA.S13109","article-title":"Treating Nausea and Vomiting in Palliative Care: A Review","volume":"6","author":"Glare P.","year":"2011","journal-title":"CIA"},{"key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00520-001-0332-1","article-title":"A Double\u2010blind, Randomised, Parallel Group, Multinational, Multicentre Study Comparing a Single Dose of ondansetron 24\u00a0mg p.o. With Placebo and Metoclopramide 10\u00a0mg t.d.s. p.o. in the Treatment of Opioid\u2010induced Nausea and Emesis in Cancer Patients","volume":"10","author":"Hardy J.","year":"2002","journal-title":"Supportive Care in Cancer"},{"key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jpainsymman.2009.11.321","article-title":"The Efficacy of Haloperidol in the Management of Nausea and Vomiting in Patients With Cancer","volume":"40","author":"Hardy J. R.","year":"2010","journal-title":"Journal of Pain and Symptom Management"},{"key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.annemergmed.2013.10.026","article-title":"Ondansetron and the Risk of Cardiac Arrhythmias: A Systematic Review and Postmarketing Analysis","volume":"64","author":"Freedman S. B.","year":"2014","journal-title":"Annals of Emergency Medicine"},{"key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrclinonc.2015.201","article-title":"Integrating Palliative Care Into the Trajectory of Cancer Care","volume":"13","author":"Hui D.","year":"2016","journal-title":"Nature Reviews Clinical Oncology"},{"key":"e_1_2_13_17_1","unstructured":"National Health and Medical Research Council (Australia).National Statement on Ethical Conduct in Human Research(2025). National Health and Medical Research Council https:\/\/www.nhmrc.gov.au."},{"key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1213\/ANE.0000000000004833","article-title":"Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting","volume":"131","author":"Gan T. J.","year":"2020","journal-title":"Anesthesia and Analgesia"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF01536922","article-title":"GR 38032F (Ondansetron), a Selective 5HT3 Receptor Antagonist, Slows Colonic Transit in Healthy Man","volume":"35","author":"Talley N. J.","year":"1990","journal-title":"Digestive Diseases and Sciences"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70208","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.70208","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:38:05Z","timestamp":1792057085000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.70208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":18,"alternative-id":["10.1111\/ajco.70208"],"URL":"https:\/\/doi.org\/10.1111\/ajco.70208","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"2026-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajco.70208"}}